Back to search

University of British Columbia

How a biosimilar switching policy impacted healthcare resource utilization and cost in British Columbia

Abstract

dc:description

The uptake of biosimilars has been slower than hoped in many jurisdictions across the globe. A concern has been raised that switch from originator to biosimilar would be associated with increased health care resource utilization (HCRU) such as increased physician visits and hospitalizations. However, the signals for these concerns have been based on small samples and potentially biased methods. In this study, administrative data were analyzed from British Columbia (BC), Canada where in the past 5 years, policies have led to patients with inflammatory bowel disease (IBD), inflammatory joint disease (IJD), and inflammatory skin disease (ISD) being switched from an originator to a biosimilar to maintain insurance coverage. A literature review was conducted using Embase, Medline, and Web of Science to update existing systematic reviews. HCRU and cost from current literature were summarized. An empirical analysis was undertaken using population-based, administrative databases (Population Data BC) from 2015 to 2021 including individuals with IBD, IJD and ISD based on ICD-9 and -10 codes. The cohort included those using originator TNF-α blockers (adalimumab, etanercept, or infliximab) before the mandatory switch policy. Descriptive analysis of HCRU components (physician visits, hospital days, emergency visits, and other medications) was conducted. An interrupted time series was used to assess the pre- and post-switch trend by treatment and cohort on total HCRU related costs. The literature review showed no pattern in increase HCRU and cost following a switch policy. The analysis on BC population included 6326, 6205, and 2474 patients in the IBD, IJD, and ISD cohorts, respectively. Based on descriptive statistics and interrupted time series analysis, no important changes in physician visits, hospital admission, or emergency visits following the policy occurred for all three cohorts. Overall, no important changes in HCRU costs due to the switch were observed, but a historical trend in decreasing hospitalizations in IBD cohort was identified. This study suggests concerns about biosimilar switch policies creating increases in other HCRU is unfounded in IBD, IJD, and ISD patients. Policy makers in other jurisdictions can feel reassured that mandatory biosimilar switching polices should not lead to increases in the cost of other healthcare resources.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Population and Public Health
Grantor dc:publisher
University of British Columbia
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Dang, HaoHung
Contributors dc:contributor
  • Harrison, Mark (Assistant professor)
  • Bansback, Nick

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/88533

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Dang, HaoHung. How a biosimilar switching policy impacted healthcare resource utilization and cost in British Columbia. master's thesis, University of British Columbia, 2024. http://hdl.handle.net/2429/88533